<DOC>
	<DOCNO>NCT01613495</DOCNO>
	<brief_summary>The purpose study learn octreotide ( Sandostatin LAR® Depot ) affect level ghrelin , hunger , body weight people Prader-Willi Syndrome .</brief_summary>
	<brief_title>Ghrelin Suppression Octreotide Prader-Willi</brief_title>
	<detailed_description>After baseline test , nurse administer monthly injection Sandostatin LAR® placebo 6 month . At end initial 6-month treatment period 4-month washout period , study subject crossover receive alternative therapy ( placebo octreotide ) additional 6 month . Subjects follow 16 month total scheduled visit : 0 , 2 , 6 , 10 , 12 , 16 month ( Table 2 ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Diagnosis PWS confirm chromosome analysis ( i.e . interstitial deletion paternallyderived chromosome 15Q , uniparental maternal disomy chromosome 15 abnormality ) Age 18 year old Written inform consent obtain ( subject guardian ) willingness comply study schedule procedure Free T4 , TSH value normal range ( without thyroxine replacement ) Subjects confirmed hypogonadism correct adequate dos sex steroid replacement , treat least 6 month prior entry change dosage study period . Patients confirm growth hormone deficiency correct adequate dos replacement , treat least 6 month prior entry change dosage study period . Symptomatic gallstone . Smokers . Alcohol consumption &gt; 2 drink per day . Exercise &gt; 30 minute 3 time week . Weight &gt; 500 lb ( exceeds limit BODPOD ) . Active pulmonary infection . Sleep disorder . Subjects exclude clinically significant disease would impact metabolic outcome body composition include diabetes mellitus , chronic inflammatory bowel disease , chronic severe liver kidney disease , heart disease , cancer , symptomatic gallstone , neurological disorder history hepatic disease ( patient minimal , i.e. , &lt; 3Xs upper limit normal LFTs indicative hepatic steatosis , MAY participate ) pregnant lactate know hypersensitivity Sandostatin acetate relate drug compound subject exhibit symptom indicative intolerance follow 100 mcg test dose Sandostatin Injection , SC subject previously receive Sandostatin® ( octreotide ) subject receive investigational drug administer receive within 30 day study entry</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>obesity</keyword>
</DOC>